Patents Issued in September 29, 2016
-
Publication number: 20160279223Abstract: The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewinigii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using the EE polypeptides, antibodies, probes, and primers for the purpose of diagnosis, therapy and production of vaccines against E. ewingii.Type: ApplicationFiled: June 6, 2016Publication date: September 29, 2016Inventor: Yasuko Rikihisa
-
Publication number: 20160279224Abstract: The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.Type: ApplicationFiled: September 18, 2014Publication date: September 29, 2016Inventors: Dominea RATHWELL, Sharavathi Guddehalli PARAMESWARAPPA, Subramanian GOVINDAN, Chakkumkal ANISH, Claney Lebev PEREIRA, Peter H. SEEBERGER, Felix BRÖCKER
-
Publication number: 20160279225Abstract: The application discloses method of immunising against Neisseria meningitidis infection comprising the steps of a) immunising a human patient at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) separately conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s); and b) immunising the human patient at a second age of between 12 and 24 months with a Neisseria meningitidis conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of N. meningitidis serogroup A capsular saccharide (MenA), N. meningitidis serogroup C capsular saccharide (MenC), N. meningitidis serogroup W135 capsular saccharide (MenW135), and N.Type: ApplicationFiled: March 17, 2014Publication date: September 29, 2016Inventors: Yaela BAINE, Jacqueline MILLER
-
Publication number: 20160279226Abstract: Described herein is the generation of optimized H5N1 and H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H5N1 and H1N1 influenza isolates. Provided herein are optimized H5N1 and H1N1 influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.Type: ApplicationFiled: November 12, 2015Publication date: September 29, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Corey J. Crevar, Donald M. Carter
-
Publication number: 20160279227Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: June 8, 2016Publication date: September 29, 2016Applicant: Icahn School of Medicine at Mount SinaiInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Publication number: 20160279228Abstract: Provided are newly identified pneumoviruses that can infect mammals, including dogs cats and potentially humans. Isolated polynucleotides and proteins of the viruses, as well as the isolated viruses themselves are provided. Included are compositions and methods for detecting the viruses, methods and compositions for prophylaxis and/or therapy of disease signs that are positively correlated with the presence of the viruses, and isolated cells comprising the viruses. Intact virions, viral proteins, and fragments thereof are also provided.Type: ApplicationFiled: June 14, 2016Publication date: September 29, 2016Inventors: Edward Dubovi, Randall W. Renshaw
-
Publication number: 20160279229Abstract: The present invention relates to a hybrid-viral vector system, in particular, but not exclusively, to a hybrid-viral vector system that can be used as a vaccine vector.Type: ApplicationFiled: June 16, 2015Publication date: September 29, 2016Inventor: John K. Rose
-
Publication number: 20160279230Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: ApplicationFiled: March 21, 2016Publication date: September 29, 2016Inventors: Shailendra Kumar Sharma, Richard Wyatt
-
Publication number: 20160279231Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.Type: ApplicationFiled: July 6, 2015Publication date: September 29, 2016Inventors: Kegong Tian, Feifei Tan, Jinzhong Sun, Xuke Zhang
-
Publication number: 20160279232Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.Type: ApplicationFiled: February 26, 2016Publication date: September 29, 2016Inventors: Kegong TIAN, Xuke ZHANG, Jinzhong SUN, Feifei TAN
-
Publication number: 20160279233Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.Type: ApplicationFiled: February 24, 2015Publication date: September 29, 2016Applicant: BTG International LimitedInventors: Robert Anderson, Tim Beissbath, Jason Tye Din
-
Publication number: 20160279234Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.Type: ApplicationFiled: March 4, 2016Publication date: September 29, 2016Applicant: SELECTA BIOSCIENCES, INC.Inventors: TAKASHI KEI KISHIMOTO, CHRISTOPHER FRASER, ROBERTO A. MALDONADO
-
Publication number: 20160279235Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.Type: ApplicationFiled: March 14, 2016Publication date: September 29, 2016Inventors: John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
-
Publication number: 20160279236Abstract: Disclosed are an immuno-enhancer composition, a use of same as a vaccine adjuvant, and a preparation method therefor. The composition comprises rapamycin and a Toll-like receptor agonist-type adjuvant.Type: ApplicationFiled: July 28, 2014Publication date: September 29, 2016Inventors: hui XIAO, Chuanping Yuan, Aiping ZANG, Min DU
-
Publication number: 20160279237Abstract: The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and a DNA component. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided.Type: ApplicationFiled: March 24, 2016Publication date: September 29, 2016Inventors: Timothy J. Miller, Mary Ann Pfannenstiel
-
Publication number: 20160279238Abstract: The invention provides methods of monitoring immunotherapy directed against alpha-synuclein by comparing a subject's constipation symptoms before treatment and at one or more times during and/or after treatment. The immunotherapeutic regime can be monitored depending on the results of treatment.Type: ApplicationFiled: November 19, 2014Publication date: September 29, 2016Inventors: Theresa Anne Neumann, Daniel Keith Ness
-
Publication number: 20160279239Abstract: Disclosed are methods, compositions and uses of concentrated formulations of anti-CD74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (SLE). In a preferred embodiment, the anti-CD74 antibody is milatuzumab (IMMU-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous administration of anti-CD74 antibody ameliorates the symptoms of autoimmune diseases, with only manageable side effects.Type: ApplicationFiled: April 18, 2016Publication date: September 29, 2016Inventors: David M. Goldenberg, William A. Wegener
-
Publication number: 20160279240Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.Type: ApplicationFiled: November 19, 2014Publication date: September 29, 2016Applicant: Board of Regents, The University of Texas SystemInventors: Mien-Chie HUNG, Hsin-Wei LIAO, Jung-Mao HSU
-
Publication number: 20160279241Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.Type: ApplicationFiled: June 16, 2016Publication date: September 29, 2016Applicant: Genentech, Inc.Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
-
Publication number: 20160279242Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from polysorbate 80, polysorbate 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.Type: ApplicationFiled: February 12, 2016Publication date: September 29, 2016Applicant: Ablynx N.V.Inventors: ANN BRIGE, Christine Labeur, Veronique De Brabandere, Marc Jozef Lauwereys
-
Publication number: 20160279243Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.Type: ApplicationFiled: June 6, 2016Publication date: September 29, 2016Inventor: John Simard
-
Publication number: 20160279244Abstract: The present invention relates to methods for transferring a nucleic acid in vivo into skin cells wherein the nucleic acid is injected by intradermal (ID) injection and is electrically transferred into skin cells with a single pulse of a High Voltage, followed, after a defined lag time, by a single pulse of Low Voltage.Type: ApplicationFiled: October 28, 2014Publication date: September 29, 2016Inventors: Pierre Langlade Demoyen, Thierry Huet, Christelle Liard, Jessie Thalmensi, Luis M. Mir, Christophe Calvet
-
Publication number: 20160279245Abstract: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a drug such as a local anesthetic, an NSAID, or a corticosteriod; and sodium lauryl sulfoacetate. The topical formulations can have enhanced physical and/or chemical stability as compared to similar formulations without sodium lauryl sulfoacetate.Type: ApplicationFiled: October 31, 2014Publication date: September 29, 2016Inventors: Wade Hull, Tejas Desai
-
Publication number: 20160279246Abstract: Methods of heterogeneous crystallization and related systems are provided. In some embodiments, a method comprises crystallizing an agent in a suspension comprising a heteronucleant and the dissolved agent. Crystallization may occur on the surface of the heteronucleant with little or no bulk crystallization and/or secondary nucleation. In some embodiments, a crystallizer may be configured to inhibit secondary nucleation and/or bulk crystallization, for example, by reducing the formation of free crystals that may serve as nucleation surfaces while allowing for adequate mass and heat transfer. In some such embodiments, the crystallizer may be designed to flow (e.g., continuously) a suspension comprising a heteronucleant and an agent in a fluidized state. The methods and systems of the present invention may be used in a wide variety of applications, including the crystallization of pharmaceutically active agents.Type: ApplicationFiled: February 26, 2016Publication date: September 29, 2016Applicant: Massachusetts Institute of TechnologyInventors: Bernhardt Levy Trout, Allan Stuart Myerson, Siva Rama Krishna Perala, Christopher James Testa, Keith Dale Jensen
-
Publication number: 20160279247Abstract: A cyclic peptide (10) includes two domains (D1,D2), each including three charged sub-domains (14, 16). The first domain (D1) includes two anionic sub-domains (14) followed by a cationic sub-domain (16). The second domain (D2) includes two cationic sub-domains (16) followed by an anionic sub-domain (14). The two domains are connected to one another and separated by a tri-glycyl linker (12). The cyclic peptide (10) is able to self-assemble into a network able to mimic an extracelluar matrix, and which promotes cell growth whilst resisting biofilm formation.Type: ApplicationFiled: November 13, 2014Publication date: September 29, 2016Applicant: THE SECRETARY OF STATE FOR BUSINESS, INNOVATION & SKILLS OF HER MAJESTY'S BRITANNIC GOVERNMENTInventors: Maxim RYADNOV, Nilofar FARUQUI, Angelo BELLA, Jascindra RAVI, Santanu RAY, Baptiste LAMARRE
-
Publication number: 20160279248Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.Type: ApplicationFiled: June 7, 2016Publication date: September 29, 2016Inventors: Charles R. Hutchinson, James R. Prudent, Jon S. Thorson
-
Publication number: 20160279249Abstract: The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety.Type: ApplicationFiled: March 21, 2014Publication date: September 29, 2016Applicants: INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS XIII PARIS NORD, UNIVERSITE PARIS DIDEROT - PARIS 7Inventors: Stephane LOYAU, Martine JANDROT-PERRUS, Didier LETOURNEUR, Frederic CHAUBET, Benoit HO-TIN-NOE, Murielle MAIRE, Jean-Baptiste MICHEL
-
Publication number: 20160279250Abstract: Methods for crystallizing a molecule of interest, such as a polypeptide, in complex with nucleic acid, including contacting the molecule of interest with selenium-derivatized nucleic acid and crystallizing the molecule of interest/selenium-derivatized nucleic acid complex are provided. Methods for determining the X-ray crystal structure of molecule of interest/selenium-derivatized nucleic acid complexes are also provided. Typically, the method of X-ray crystal structural determination includes selenium single-wavelength anomalous phasing of the selenium-derivatized nucleic acid. In some embodiments the phases for the X-ray crystal structure of the molecule of interest are not provided from another crystal. Also disclosed are methods of affecting a biological process by administering a functional nucleic acid to a cell or a subject and/or by bringing into contact a nuclease and a functional nucleic acid, where the functional nucleic acid is selenium-derivatized nucleic acid.Type: ApplicationFiled: November 21, 2014Publication date: September 29, 2016Inventor: Zhen HUANG
-
Publication number: 20160279251Abstract: Provided herein are particles assemblies including a shell surrounding a core. The shell includes a particle-stabilizing random copolymer. The core includes a core random copolymer. The particle assemblies have a biomimetic design in which the polymeric components containing discrete chemical and biological functionalities are designed to spontaneously self-assemble into particles. Also provided herein are random copolymers having conjugated therapeutic agents that can be cleaved from the copolymers by an enzyme or water.Type: ApplicationFiled: November 12, 2014Publication date: September 29, 2016Applicant: University of Washington through its Center for CommercializationInventors: Patrick S. Stayton, Anthony Convertine, Daniel M. Ratner, Selvi Srinivasan, Debobrato Das, Fang-Yi Su, Jasmin Chen, David Yee-Shawn Chiu, Daniel Douglas Lane
-
Publication number: 20160279252Abstract: Provided herein are conjugates for inducing tolerance of a coagulation factor protein, wherein the conjugate comprises a coagulation factor protein or an antigenic fragment or variant thereof and a Siglec ligand. Pharmaceutical compositions, methods and kits comprising the conjugates are also provided.Type: ApplicationFiled: April 27, 2014Publication date: September 29, 2016Inventor: Fred Jullien ASWAD
-
Publication number: 20160279253Abstract: Disclosed herein are an N-terminal modified PEG-TRAIL conjugates and methods of making and using thereof. The PEG-TAIL conjugates have bioactivity that is substantially similar to that of native TRAIL coupled with an extended in vivo half-life and enhanced stability. The disclosed PEG-TRAIL conjugates exhibit significantly reduced hepatotoxicity when compared to that of non-PEGylated trimeric TRAIL. The disclosed methods of making the PEG-TRAIL conjugates provide a homogeneous, highly pure, form of N-terminal modified PEG-TRAIL. Compared to native TRAIL, the PEG-TRAIL conjugates exhibits high solubility and solution stability. The PEG-TRAIL conjugates are useful in preventing and treating proliferative or autoimmune diseases.Type: ApplicationFiled: April 25, 2016Publication date: September 29, 2016Inventors: Kang Choon Lee, Seulki Lee, Eun Ji Park
-
Publication number: 20160279254Abstract: This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell.Type: ApplicationFiled: December 28, 2015Publication date: September 29, 2016Inventors: WOUTER VERVECKEN, KATHLEEN CAMILLA TELESPHORE ALIDA MARIA PIENS, JAN ROBERT LUDO STOUT, GWENDA NOËLLA PYNAERT
-
Publication number: 20160279255Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of peptide modulators of PKC isozymes (“PMPKCs”), and/or naturally or artificially occurring derivatives, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to PMPKCs and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.Type: ApplicationFiled: November 6, 2015Publication date: September 29, 2016Inventor: D. Travis Wilson
-
Publication number: 20160279256Abstract: In some embodiments, the present disclosure pertains to compositions for nucleic acid delivery into cells. In some embodiments, the composition comprises: (1) a cationic polymer unit comprising a plurality of polymeric arms, where the plurality of polymeric arms comprise poly(aspartic acid) derivatives; and (2) a nucleic acid associated with the cationic polymer unit. In some embodiments, the cationic polymer unit comprises a linker covalently associated with the plurality of polymeric arms. In some embodiments, the cationic polymer unit has a dendritic shape. In some embodiments, the cationic polymer unit has a star-like shape. In some embodiments, the cationic polymer unit is biodegradable. Further embodiments of the present disclosure pertain to methods of delivering a nucleic acid into cells by introducing into the cells one or more of the compositions of the present disclosure.Type: ApplicationFiled: November 13, 2013Publication date: September 29, 2016Applicant: Baylor College of MedicineInventors: Jin Wang, Fude Feng
-
Publication number: 20160279257Abstract: Provided are methods and compositions relating to conjugation of nucleic acids and proteins of interest under conditions that maintain protein activity. The nucleic acid-protein conjugates may be used in nucleic acid nanostructures such as those generated using DNA origami methods.Type: ApplicationFiled: July 10, 2014Publication date: September 29, 2016Applicants: President and Fellows of Harvard College, Children's Medical Center CorporationInventors: Mounir Ahmad Koussa, Wesley Philip Wong
-
Publication number: 20160279258Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.Type: ApplicationFiled: November 21, 2014Publication date: September 29, 2016Inventors: Jesper VALBJØRN, Xiaona JING, Kelly Ann ROBY, Timothy Warren PAUL, Gregory Allan SACHA, Nathan Alan PEASE, Bodil WILLUMSEN
-
Publication number: 20160279259Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: June 13, 2016Publication date: September 29, 2016Applicant: Daiichi Sankyo Company, LimitedInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Publication number: 20160279260Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.Type: ApplicationFiled: June 14, 2016Publication date: September 29, 2016Applicant: Genentech, Inc.Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben
-
Publication number: 20160279261Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.Type: ApplicationFiled: June 14, 2016Publication date: September 29, 2016Applicant: Genentech, Inc.Inventors: Ho Huat Lee, Moana Tercel, John A. Flygare, Janet Gunzner-Toste, Thomas H. Pillow, Brian Safina, Leanna Staben, Vishal Verma, BinQing Wei, Guiling Zhao
-
Publication number: 20160279262Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalizing into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: ApplicationFiled: June 9, 2016Publication date: September 29, 2016Inventors: James D. Marks, Marie Alix Poul
-
Publication number: 20160279263Abstract: A composition having general structure (1); wherein the P-gp substrate is a substrate for P-glycoprotein; the linker is a biocompatible polymeric moiety; the drug-loaded carrier comprises a biocompatible framework carrying at least one drug; and the straight line shown in Formula (1) between the drug-loaded carrier and linker represents a first bond, and the straight line shown in Formula (1) between the linker and P-gp substrate represents a second bond. Also described herein are pharmaceutical compositions containing the above compositions, as well as methods for using these compositions for targeted delivery of a drug to cells expressing higher levels of P-glycoprotein compared to other cells in a mammal, for the treatment of various diseases or conditions, such as cancer and neurological conditions.Type: ApplicationFiled: November 14, 2013Publication date: September 29, 2016Applicant: CORNELL UNIVERSITYInventors: David PUTNAM, Lindsey CRAWFORD
-
Publication number: 20160279264Abstract: A method to form a lipid-containing aminoglycoside-based polymer, where the method includes reacting an aminoglycoside with a diepoxide to form an aminoglycoside-based polymeric material, and then reacting the aminoglycoside-based polymeric material with an acyl chloride to form the lipid-containing aminoglycoside-based polymer.Type: ApplicationFiled: November 5, 2014Publication date: September 29, 2016Inventors: Kaushal REGE, Bhavani MIRYALA, Thrimoorthy POTTA
-
Publication number: 20160279265Abstract: The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.Type: ApplicationFiled: October 29, 2014Publication date: September 29, 2016Applicants: President and Fellows of Harvard College, President and Fellows of Harvard CollegeInventors: Constance L. Cepko, Wenjun Xiong
-
Publication number: 20160279266Abstract: The present invention relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector reside in the presence of a translation enhancer (TE) and a nuclear retention element (NRS), especially when the latter is the “Expression and Nuclear Retention Element” (ENE) of Kaposi's sarcoma associated Herpes virus (KSHV).Type: ApplicationFiled: November 12, 2014Publication date: September 29, 2016Applicant: VRIJE UNIVERSITEIT BRUSSELInventors: Carlo HEIRMAN, Kristiaan THIELEMANS
-
Publication number: 20160279267Abstract: In one example, a system electrically stimulates target cells of a living animal using an elongated structure, a modulation circuit and a light pathway such as provided by an optical fiber arrangement. The elongated structure is for insertion into a narrow passageway in the animal such that an end of the elongated structure is sufficiently near the target cells to deliver stimulation thereto. The modulation circuit is for modulating the target cells while the elongated structure is in the narrow passageway, where the modulation circuit is adapted to deliver viral vectors through the elongated structure for expressing light responsive proteins in the target cells. The light pathway is used for stimulating the target cells by delivering light to the light-responsive proteins in the target cells.Type: ApplicationFiled: May 16, 2016Publication date: September 29, 2016Inventors: Karl Deisseroth, Alexander Aravanis, Feng Zhang, M. Bret Schneider, Jaimie M. Henderson
-
Publication number: 20160279268Abstract: This disclosure relates to luciferin amides of formula (I) shown below: Each variable in formula (I) is defined in the specification. These compounds can be used to detect fatty acid amide hydrolase activities in vitro, in live cells, or in vivo.Type: ApplicationFiled: June 3, 2016Publication date: September 29, 2016Inventor: Stephen C. Miller
-
Publication number: 20160279269Abstract: The present invention provides an aqueous, excipient solution suitable for diluting a diagnostic composition comprising a contrast agent. The excipient solution comprises a sodium ion concentration of about 100-140 mM and a calcium ion concentration of about 0.8-1.2 mM. Alternatively, the molar ratio between sodium ion concentration and calcium ion concentration is between about 80 and 175. Also provided are methods of making and using the excipient solution, as well as a kit comprising the excipient solution.Type: ApplicationFiled: March 6, 2014Publication date: September 29, 2016Inventor: Dirk-Jan In't Veld
-
Publication number: 20160279270Abstract: Embodiments of the present disclosure provide for nanoprobes, methods of imaging, methods of imaging a target, methods of making nanoprobes, and the like.Type: ApplicationFiled: May 25, 2016Publication date: September 29, 2016Inventors: Aihua Fu, Shan X. Wang, Sanjiv S. Gambhir
-
Publication number: 20160279271Abstract: A novel near-infrared dye-bound transferrin exhibiting a high absorption coefficient in the near-infrared wavelength region, a high tumor accumulation property, a high tumor/blood ratio and a high imaging contrast, and a contrast agent for photoacoustic imaging, including the same are provided. A compound is provided in which transferrin and an organic dye having a specified structure that absorbs light in the near-infrared wavelength region are covalently bound.Type: ApplicationFiled: March 15, 2016Publication date: September 29, 2016Inventors: Fumio Yamauchi, Kengo Kanazaki, Satoshi Ogawa
-
Publication number: 20160279272Abstract: The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.Type: ApplicationFiled: November 12, 2014Publication date: September 29, 2016Inventors: John Fitzmaurice VALLIANT, Eric Steven BURAK, Neil Grant COCKBURN, Alla DARWISH, Joel Adamson DREWRY, John Richard FORBES, Meiduo HU, Ryan Wayne SIMMS, Karin Ann STEPHENSON, Tao WU